FDA Roundup: May 03, 2024
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced the...
Source: prnewswire.com
Negative Symptoms News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Negative Symptoms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Negative Symptoms Today - Breaking & Trending Today
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Acadia Pharmaceuticals Inc. today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement...
Source: lelezard.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript February 27, 2024 ACADIA Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $0.28 EPS, expectations were $0.32. ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
Source: yahoo.com
FDA Issues CRL for Roluperidone for Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores.
Source: hcplive.com
Schizophrenia Research Roundup: February 16, 2024
What is new in research on schizophrenia?
Source: psychiatrictimes.com